[5] Hussain M, Tombal B, Saad F, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial[J]. Journal of Clinical...
National Comprehensive Cancer Network (NCCN) riSK classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients 癌症病人风险分类生物化学前列腺切除术预言中国网络摘要:Hua XuDepartment of UrologyYao ZhuDepartment of OncologyBo Dai...
2023 年发布的PLCOm2012-update则对美国各族裔间进一步平衡,与USPSTF 2021 相比,保证筛查性能的同时提高了模型在跨种族族裔中的表现[19]。 基于以上结果,2023 年版NCCN指南首次鼓励使用“风险计算器”计算肺癌风险(https://brocku. ca/lung-canc...
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where ...
Breast Cancer Risk Reduction Version 1.2018 Lung Cancer Screening Version 3.2018 NCCN Guidelines for Supportive Care NCCN Framework for Resource Stratification - Palliative Care Version 1.2018 (Preliminary) Basic Rescources Core Resources Enhanced Resources ...
Cervical Cancer Screening Colorectal Cancer Screening Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Genetic/Familial High-Risk Assessment:Colorectal Lung Cancer Screening Prostate Cancer Early Detection NCCN Guidelines for Supportive Care Adult Cancer Pain Antiemesis Cancer...
NCCN临床实践指南：前列腺癌（2022.V2）更新解读 林琦孔家瑾陈伟 ［关键词］前列腺癌；美国国家综合癌症网络；解读 前列腺癌是男性泌尿生殖系统中最常见的恶性肿瘤，根据WHO2018年的统计数据，在世界范围内，其发病率在男性所有恶性肿瘤中位居第2位。在美国，前列腺癌的发病率居男性恶性肿瘤的首位，死亡率居男性恶性肿瘤...
Active surveillance or watchful waiting has been an option for low-risk prostate cancer, but the NCCN now recommends that it be the only initial treatment for many men.
1、2020 NCCN前列腺癌指南V2版更新National ComprehensiveCancer Network"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)Prostate CancerVersion 2.2020 May 21. 2020NCCN.orgContinue5月15日,FDA加速批准卢卡帕利(Rucaparib )用于治疗预先接 受过雄激素受体靶向疗法和紫杉烷类化疗的BRCA突变(胚系和/或 ...
NCCNProstateCancerDmsunnion Network SYSTEMICTHERAPYFORCASTRATION-SENSITIVEPROSTATECANCER Monitortingtpreferred)| Mo*s,or ADruuu|See |Studies Systemis |Physicalexam+nogatlve Therapyfot PSAovery3-6mofordistant MOCRPC ADTwithoneofthefollowing:motstase ...